Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT01367275
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Brivanib — DRUG
    800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
  • Irinotecan — DRUG
    180 mg/m\^2 by vein on Day 1 of a 14 day cycle.

Study Details

The goal of this clinical research study is to learn if adding brivanib to irinotecan can help control the disease in patients with colorectal cancer that has spread. The safety of this drug combination will also be studied.

Key Dates

Start date
Aug 31, 2011
Status verified
Sep 2020
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Brivanib + Irinotecan
    Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m\^2 on Day 1.

Primary Outcome Measure

Number of Participants With Median Progression-Free Survival (PFS) [ Time Frame: Enrollment (baseline) to disease progression or death, followed each 14 day treatment then every 2 months,up to 100 week ]

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
UT MD Anderson Cancer Center· Houston, TX

Related Studies